BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25322277)

  • 1. A case of severe hyperaldosteronism caused by a de novo mutation affecting a critical salt bridge Kir3.4 residue.
    Monticone S; Bandulik S; Stindl J; Zilbermint M; Dedov I; Mulatero P; Allgaeuer M; Lee CC; Stratakis CA; Williams TA; Tiulpakov A
    J Clin Endocrinol Metab; 2015 Jan; 100(1):E114-8. PubMed ID: 25322277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. a Novel Y152C KCNJ5 mutation responsible for familial hyperaldosteronism type III.
    Monticone S; Hattangady NG; Penton D; Isales CM; Edwards MA; Williams TA; Sterner C; Warth R; Mulatero P; Rainey WE
    J Clin Endocrinol Metab; 2013 Nov; 98(11):E1861-5. PubMed ID: 24037882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyuric-polydipsic syndrome in a pediatric case of non-glucocorticoid remediable familial hyperaldosteronism.
    Mussa A; Camilla R; Monticone S; Porta F; Tessaris D; Verna F; Mulatero P; Einaudi S
    Endocr J; 2012; 59(6):497-502. PubMed ID: 22447138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Familial hyperaldosteronism type III a novel case and review of literature.
    Pons Fernández N; Moreno F; Morata J; Moriano A; León S; De Mingo C; Zuñiga Á; Calvo F
    Rev Endocr Metab Disord; 2019 Mar; 20(1):27-36. PubMed ID: 30569443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discordant genotype-phenotype correlation in familial hyperaldosteronism type III with KCNJ5 gene mutation: a patient report and review of the literature.
    Adachi M; Muroya K; Asakura Y; Sugiyama K; Homma K; Hasegawa T
    Horm Res Paediatr; 2014; 82(2):138-42. PubMed ID: 24819081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional characterization of two novel germline mutations of the KCNJ5 gene in hypertensive patients without primary aldosteronism but with ACTH-dependent aldosterone hypersecretion.
    Sertedaki A; Markou A; Vlachakis D; Kossida S; Campanac E; Hoffman DA; Sierra ML; Xekouki P; Stratakis CA; Kaltsas G; Piaditis GP; Chrousos GP; Charmandari E
    Clin Endocrinol (Oxf); 2016 Dec; 85(6):845-851. PubMed ID: 27293068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Familial hyperaldosteronism type III.
    Monticone S; Tetti M; Burrello J; Buffolo F; De Giovanni R; Veglio F; Williams TA; Mulatero P
    J Hum Hypertens; 2017 Dec; 31(12):776-781. PubMed ID: 28447626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism.
    Mulatero P; Tauber P; Zennaro MC; Monticone S; Lang K; Beuschlein F; Fischer E; Tizzani D; Pallauf A; Viola A; Amar L; Williams TA; Strom TM; Graf E; Bandulik S; Penton D; Plouin PF; Warth R; Allolio B; Jeunemaitre X; Veglio F; Reincke M
    Hypertension; 2012 Feb; 59(2):235-40. PubMed ID: 22203740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel KCNJ5-insT149 somatic mutation close to, but outside, the selectivity filter causes resistant hypertension by loss of selectivity for potassium.
    Kuppusamy M; Caroccia B; Stindl J; Bandulik S; Lenzini L; Gioco F; Fishman V; Zanotti G; Gomez-Sanchez C; Bader M; Warth R; Rossi GP
    J Clin Endocrinol Metab; 2014 Sep; 99(9):E1765-73. PubMed ID: 25057880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of KCNJ5 in familial and sporadic primary aldosteronism.
    Mulatero P; Monticone S; Rainey WE; Veglio F; Williams TA
    Nat Rev Endocrinol; 2013 Feb; 9(2):104-12. PubMed ID: 23229280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insights into aldosterone-producing adenomas and hereditary aldosteronism: mutations in the K+ channel KCNJ5.
    Scholl UI; Lifton RP
    Curr Opin Nephrol Hypertens; 2013 Mar; 22(2):141-7. PubMed ID: 23318698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatic ATP1A1, ATP2B3, and KCNJ5 mutations in aldosterone-producing adenomas.
    Williams TA; Monticone S; Schack VR; Stindl J; Burrello J; Buffolo F; Annaratone L; Castellano I; Beuschlein F; Reincke M; Lucatello B; Ronconi V; Fallo F; Bernini G; Maccario M; Giacchetti G; Veglio F; Warth R; Vilsen B; Mulatero P
    Hypertension; 2014 Jan; 63(1):188-95. PubMed ID: 24082052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role for germline mutations and a rare coding single nucleotide polymorphism within the KCNJ5 potassium channel in a large cohort of sporadic cases of primary aldosteronism.
    Murthy M; Xu S; Massimo G; Wolley M; Gordon RD; Stowasser M; O'Shaughnessy KM
    Hypertension; 2014 Apr; 63(4):783-9. PubMed ID: 24420545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel point mutation in the KCNJ5 gene causing primary hyperaldosteronism and early-onset autosomal dominant hypertension.
    Charmandari E; Sertedaki A; Kino T; Merakou C; Hoffman DA; Hatch MM; Hurt DE; Lin L; Xekouki P; Stratakis CA; Chrousos GP
    J Clin Endocrinol Metab; 2012 Aug; 97(8):E1532-9. PubMed ID: 22628607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel KCNJ5 mutations in sporadic aldosterone-producing adenoma reduce Kir3.4 membrane abundance.
    Cheng CJ; Sung CC; Wu ST; Lin YC; Sytwu HK; Huang CL; Lin SH
    J Clin Endocrinol Metab; 2015 Jan; 100(1):E155-63. PubMed ID: 25347571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A revised mechanism of action of hyperaldosteronism-linked mutations in cytosolic domains of GIRK4 (KCNJ5).
    Shalomov B; Handklo-Jamal R; Reddy HP; Theodor N; Bera AK; Dascal N
    J Physiol; 2022 Mar; 600(6):1419-1437. PubMed ID: 34957562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetics of primary aldosteronism.
    Funder JW
    Front Horm Res; 2014; 43():70-8. PubMed ID: 24943299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mosaicism for KCNJ5 Causing Early-Onset Primary Aldosteronism due to Bilateral Adrenocortical Hyperplasia.
    Maria AG; Suzuki M; Berthon A; Kamilaris C; Demidowich A; Lack J; Zilbermint M; Hannah-Shmouni F; Faucz FR; Stratakis CA
    Am J Hypertens; 2020 Feb; 33(2):124-130. PubMed ID: 31637427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutated KCNJ5 activates the acute and chronic regulatory steps in aldosterone production.
    Hattangady NG; Karashima S; Yuan L; Ponce-Balbuena D; Jalife J; Gomez-Sanchez CE; Auchus RJ; Rainey WE; Else T
    J Mol Endocrinol; 2016 Jul; 57(1):1-11. PubMed ID: 27099398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in KCNJ5 determines presentation and likelihood of cure in primary hyperaldosteronism.
    Ip JC; Pang TC; Pon CK; Zhao JT; Sywak MS; Gill AJ; Soon PS; Sidhu SB
    ANZ J Surg; 2015 Apr; 85(4):279-83. PubMed ID: 24274318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.